Skip to main navigation
Skip to search
Skip to main content
The Ohio State University Home
Search content at The Ohio State University
Home
Profiles
Research units
Research output
Projects
Thalidomide-induced severe hepatotoxicity
A. James Hanje
, Jennifer L. Shamp
, Fred B. Thomas
, Greg M. Meis
Center for Clinical and Translational Science
Internal Medicine
Internal Medicine - Gastroenterology, Hepatology & Nutrition
Research output
:
Contribution to journal
›
Article
›
peer-review
22
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Thalidomide-induced severe hepatotoxicity'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Thalidomide
100%
Severe Hepatotoxicity
100%
Liver Function Tests
28%
Aspartate Aminotransferase
28%
Alanine Aminotransferase Level
28%
Therapeutic Agents
14%
Nonalcoholic Steatohepatitis
14%
Multiple Myeloma
14%
Biopsy Specimen
14%
Adverse Effects
14%
Liver Disease
14%
Steatosis
14%
Relapsed or Refractory multiple Myeloma
14%
Liver Biopsy
14%
Hepatotoxicity
14%
Acute Injury
14%
Older Women
14%
Possible Complications
14%
Other-report
14%
Upper Normal Limit
14%
Serious Adverse Effects
14%
Pre-existing Liver Disease
14%
Bridging Fibrosis
14%
Medicine and Dentistry
Liver Toxicity
100%
Thalidomide
100%
Liver Disease
28%
Adverse Event
28%
Multiple Myeloma
28%
Alanine Aminotransferase
28%
Liver Function Test
28%
Aspartate Aminotransferase
28%
Therapeutic Agent
14%
Nonalcoholic Fatty Liver
14%
Fibrosis
14%
Clinician
14%
Liver Biopsy
14%
Dexamethasone
14%
Steatosis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Hepatotoxicity
100%
Thalidomide
100%
Liver Disease
28%
Adverse Event
28%
Multiple Myeloma
28%
Alanine Aminotransferase
28%
Aspartate Aminotransferase
28%
Nonalcoholic Fatty Liver
14%
Fibrosis
14%
Steatosis
14%
Dexamethasone
14%
Immunology and Microbiology
Thalidomide
100%
Liver Function
28%
Multiple Myeloma
28%
Alanine Aminotransferase Level
28%
Steatohepatitis
14%
Dexamethasone
14%